Boothbay Fund Management, LLC Altimmune, Inc. Transaction History

Boothbay Fund Management, LLC

9 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2023 May 15, 2023	BUY	$4.19 - $16.83 $517,959 - $2.08 Million	123,618 Added 236.63%	175,860 $742,000
Q4 2022 Feb 14, 2023	SELL	$8.74 - $16.45 $303,007 - $570,305	-34,669 Reduced 39.89%	52,242 $859,000
Q3 2022 Nov 14, 2022	SELL	$10.67 - $22.41 $441,439 - $927,146	-41,372 Reduced 32.25%	86,911 $1.11 Million
Q2 2022 Aug 15, 2022	BUY	$3.94 - $11.77 $505,435 - $1.51 Million	128,283 New	128,283 $1.5 Million
Q2 2021 Aug 16, 2021	SELL	$9.85 - $16.46 $192,025 - $320,887	-19,495 Closed	0 $0
Q1 2021 May 17, 2021	BUY	$12.71 - $24.31 $20,691 - $39,576	1,628 Added 9.11%	19,495 $275,000
Q4 2020 Feb 12, 2021	BUY	$7.84 - $14.22 $45,276 - $82,120	5,775 Added 47.76%	17,867 $202,000
Q3 2020 Nov 16, 2020	BUY	$9.93 - $33.26 $804 - $2,694	81 Added 0.67%	12,092 $160,000
Q2 2020 Aug 14, 2020	BUY	$2.9 - $10.71 $34,831 - $128,637	12,011 New	12,011 $129,000

186

39.3M

913K

743K

Ticker ALT
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 49,025,300
Market Cap $370M
Description
Altimmune, Inc., a clinical stage biopharmaceutical company, focuses on developing treatments for obesity and liver diseases. The company's lead product candidate, pemvidutide (proposed INN, formerly known as ALT-801), is a GLP-1/glucagon dual receptor agonist that is in Phase 1b trial for the treatment of obesity and non-alcoholic steatohepatit...

Get notified when there are updates to the investment portfolio of Boothbay Fund Management, LLC, based on Form 13F filings with the SEC.

Stay updated on Boothbay Fund Management, LLC with notifications on news.